Business development

Biomay has entered into partnerships with several leading players in the field of allergy immunotherapy and diagnostics based on its first and second generation recombinant allergens.

Biomay is interested in entering into discussions with pharmaceutical companies for licensing and/or co-development of its innovative pipeline candidates. Preferably we will enter into such partnerships following successful clinical proof of concept.